Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 33 |
| Active Pipeline (Recruiting Now) | 10 (7) |
| Completed vs Stopped Early | 13 / 10 (30.3%) |
| Median Closed Actual Enrollment | 103 participants |
| Physical Hospital Site Disclosure | 95.9% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Emory Winship Cancer Institute | Atlanta, GA | 4 |
| Huntsman Cancer Institute at University of Utah | Salt Lake City, UT | 3 |
| UT Southwestern Simmons Cancer Center | Dallas, TX | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07516951 | A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis | Phase II | RECRUITING |
| NCT06328608 | A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease | Phase II/III | RECRUITING |
| NCT05710692 | Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease | Phase II/III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Chiesi Farmaceutici S.p.A Interactive Dossier, benchmark peers in Respiratory and Pulmonary, or review the Healthcare Price & Patent Cliff Crosswalk.